|
| Study | Calendar period | total | Sources of RA patients | Style | Mean/median follow-up (year) | Breast cancer
(observed/expected) | Adjusted factors for SIR | SIR (95% CI) |
|
| Mercer et al., (2013) [5] | 2002–2009 | 3,771 | The BSRBR (British Society for Rheumatology Biologics Register) Control Centre Consortium | Population-based | 3.7 | 30/28.16 | Age, sex, and calendar year | 1.07 (0.72–1.52) |
| Infante-Rivard et al., (2012) [12] | 1976–2001 | 1,437 | Quebec Tumuor Registry, Quebec Institute of Statistics and Health, Canada | Population-based | 5 | 22/25.01 | Age, sex, and calendar year | 0.88 (0.58–1.34) |
| Yamada et al., (2011) [6] | 2001–2005 | 7,566 | IORRA (Institute of Rheumatology, Rheumatoid Arthritis formally known as J-ARAMIS) | Population-based | NA | 20 | Age and sex | 1.05 (0.64–1.62) |
| Chen et al., (2011) [7] | 1996–2007 | 23,644 | The National Health Research Institute of Taiwan | Population-based | 5.90 ± 2.87 | 123/101.44 | Age, sex, and calendar year | 1.21 (1.19–1.23) |
| Parikh-Patel et al., (2009) [13] | 1991–2002 | 84,475 | California’s Office of Statewide Planning and Health Development | Hospital-based | 4.8 | 842/1343.5 | Age, sex, and race/ethnicity | 0.63 (0.59–0.67) |
| Abásolo et al., (2008) [14] | 1999–2005 | 789 | The EMECAR cohort (Estudio de la Morbilidad y Expresion Clinica de la Artritis Reumatoide) | Population-based | 3.95 | 2 | Age and sex | 0.90 (0.10–3.20) |
| Hemminki et al., (2008) [15] | 1980–2004 | 42,262 | The Swedish Hospital Discharge Register | Hospital-based | NA | 642 | Age, sex, period, region, and socioeconomic status | 0.97 (0.90–1.05) |
| Buchbinder et al., (2008) [16] | 1986–1998 | 458 | Victorian State Cancer Registry | Population-based | 9.3 | 4/6.1 | Age, sex, and calendar year | 0.70 (0.20–1.70) |
|
Wolfe and Michaud (2007) [17] | 1998–2005 | 13,869 | The US National Data Bank for Rheumatic Diseases | Population-based | 4.1 | 102 | Age and sex | 0.80 (0.60–0.90) |
| Setoguchi et al., (2006) [18] | NA | 29,422 | Health care utilization databases from US and Canada | Population-based | NA | 112/126.6 | Age and sex | 0.90 (0.73–1.06) |
| Askling et al., (2005) [19] | 1990–2003 | 53,067 | The Swedish Inpatient Register | Hospital-based | 5.6 | 471 | Age, sex, and calendar year | 0.83 (0.76–0.91) |
| Askling et al., (2005) [19] (Early RA) | 1995–2003 | 3,703 | The Early Arthritis Register | Population-based | 3.6 | 13 | Age, sex, and calendar year | 0.60 (0.30–1.00) |
| Askling et al., (2005) [19] (TNF antagonist RA) | 1999–2003 | 4,160 | Swedish structured postmarketing surveillance program | Population-based | 2.3 | 8 | Age, sex, and calendar year | 0.40 (0.20–0.90) |
| Thomas et al., (2000) [20] | 1981–1996 | 26,623 | Scottish Cancer Registry | Hospital-based | 5.3 | 249 | Age, sex, site, and calendar year | 0.95 (0.83–1.07) |
| Cibere et al., (1997) [21] | 1966–1974 | 862 | Rheumatic Disease Unit | Population-based | 17.4 | 18/22.8 | Age, sex, and calendar year | 0.90 (0.46–1.24) |
|
Mellemkjær et al., (1996) [22] | 1977–1987 | 20,699 | Danish Hospital Discharge Register | Hospital-based | 7 | 186/229.8 | Age, sex, and calendar year | 0.80 (0.70–0.90) |
| Moritomo et al., (1995) [23] | 1980–1989 | 655 | Center for Adult Diseases, Osaka, Japan | Population-based | 10 | 3/1.79 | Age, sex, site, and calendar year | 1.68 (0.34–4.91) |
| Gridley et al., (1993) [24] | 1965–1983 | 11,683 | Swedish Hospital Inpatient Register | Hospital-based | 8.6 | 106 | Age, sex, site, and calendar year | 0.79 (0.60–1.00) |
|
